摘要
目的评价转化生长因子βⅡ受体(TGF-βRⅡ)与人表皮生长因子受体2(HER2)阴性乳腺癌患者预后的关系。方法用免疫组化法检测102例HER2阴性乳腺癌组织中转化生长因子β1(TGF-β1)和TGF-βⅡ的表达,分析其与临床病理特征的关系。结果 HER2阴性乳腺癌患者TGF-βⅡ和TGF-β1阳性表达率分别为39.22%(40/102)和31.37%(32/102)。TGF-βⅡ阳性者5年生存率(77.50%)显著高于TGF-βⅡ阴性者(53.23%),TGF-β1阳性者5年生存率(71.88%)显著高于TGF-β1阴性者(45.71%);Cox比例风险模型显示,TGF-βⅡ、雌激素受体(ER)、肿瘤大小和淋巴结转移是影响HER2阴性乳腺癌患者预后的独立因素。结论 TGF-βⅡ可作为判断HER2阴性乳腺癌患者预后的指标。
Objective To explore the relation between transforming growth factor-βtype II receptor ( TGF-βRⅡ) and the prognosis of hu-man epidermal growth factor receptor 2 ( HER2 ) -negative breast concer patients.Methods The expressions of TGF -β1 and TGF-βⅡwere de-tected by immunohistochemical in 102 HER2-negative breast tumours pa-tients.The correlation between the expressions and the clinicopathologic characteristics was analyzed.Results The positive expression rates of TGF-βⅡand TGF-β1 detected in HER2-negative breast cancer pa-tients were 39.22%and 31.37%.The 5-years overall survival rate of the TGF-βⅡ-positive patients (77.50%) was significantly higher than that of TGF-βⅡ-negitive patients (53.23%).The 5-years overall survival rate of the TGF-β1-positive patients (71.88%) was significantly higher than that of TGF -β1-negitive patients (45.71%).The COX proportion-al hazard model showed that expressions of TGF -βⅡand estrogen recep-tor ,tumor size and lymph node involvement were independent factors influ -encing on prognostic.Conclusion TGF-βⅡcan be used to judge the progrosis of HER2-negative breast cancer patients .
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2014年第4期306-308,共3页
The Chinese Journal of Clinical Pharmacology